<table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4 Clarithromycin Susceptibility Test Results and Clinical/Bacteriological Outcomes
</caption>
<col span="1" width="13.717%"></col>
<col span="1" width="14.000%"></col>
<col span="1" width="26.767%"></col>
<col span="1" width="13.217%"></col>
<col span="1" width="10.717%"></col>
<col span="1" width="10.717%"></col>
<col span="1" width="10.867%"></col>
<tbody>
<tr>
<td> Clarithromycin Susceptibility Test Results and Clinical/Bacteriological Outcomes <sup>a</sup>
</td>
</tr>
<tr>
<td> Clarithromycin Pretreatment Results
</td>
<td> Clarithromycin Post-treatment Results
</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td> <content stylecode="italics">H. pylori</content> negative – eradicated
</td>
<td> <content stylecode="italics">H. pylori</content> positive – not eradicated
</td>
</tr>
<tr>
<td> Post-treatment susceptibility results
</td>
</tr>
<tr>
<td> S <sup>b</sup>
</td>
<td> I <sup>b</sup>
</td>
<td> R <sup>b</sup>
</td>
<td> No MIC
</td>
</tr>
<tr>
<td> Dual Therapy – (omeprazole 40 mg once daily/clarithromycin 500 three times daily for 14 days followed by omeprazole 20 mg once daily for another 14 days) (Studies 4, 5)
</td>
</tr>
<tr>
<td> Susceptible <sup>b</sup>
</td>
<td> 108
</td>
<td> 72
</td>
<td> 1
</td>
<td> </td>
<td> 26
</td>
<td> 9
</td>
</tr>
<tr>
<td> Intermediate <sup>b</sup>
</td>
<td> 1
</td>
<td> </td>
<td> </td>
<td> </td>
<td> 1
</td>
<td> </td>
</tr>
<tr>
<td> Resistant <sup>b</sup>
</td>
<td> 4
</td>
<td> </td>
<td> </td>
<td> </td>
<td> 4
</td>
<td> </td>
</tr>
<tr>
<td> Triple Therapy – (omeprazole 20 mg twice daily/clarithromycin 500 mg twice daily/amoxicillin 1 g twice daily for 10 days – Studies 1, 2, 3; followed by omeprazole 20 mg once daily for another 18 days – Studies 1, 2)
</td>
</tr>
<tr>
<td> Susceptible <sup>b</sup>
</td>
<td> 171
</td>
<td> 153
</td>
<td> 7
</td>
<td> </td>
<td> 3
</td>
<td> 8
</td>
</tr>
<tr>
<td> Intermediate<sup>b</sup>
</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Resistant <sup>b</sup>
</td>
<td> 14
</td>
<td> 4
</td>
<td> 1
</td>
<td> </td>
<td> 6
</td>
<td> 3
</td>
</tr>
<tr>
<td> <paragraph>
<sup>a</sup>Includes only patients with pretreatment clarithromycin susceptibility test results
</paragraph>
</td>
</tr>
<tr>
<td> <paragraph>
<sup>b</sup>Susceptible (S) MIC ≤ 0.25 μg/mL, Intermediate (I) MIC 0.5 – 1.0 μg/mL, Resistant (R) MIC ≥ 2 μg/mL
</paragraph>
</td>
</tr>
</tbody>
</table>